Aetna modified CPB 0641 covering adoptive immunotherapy and cellular therapy, effective October 2, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0641 on October 2, 2025. This coverage policy governs adoptive immunotherapy and cellular therapy services billed under HCPCS codes S2107 and M0075, with related procedures billed under CPT codes 36511, 86357, 88230, 88237, and 88239. The update affects oncology, hematology, and infectious disease billing teams who submit claims for these services to Aetna.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Adoptive Immunotherapy and Cellular Therapy |
| Policy Code | CPB 0641 |
| Change Type | Modified |
| Effective Date | October 2, 2025 |
| Impact Level | High |
| Specialties Affected | Oncology, hematology, infectious disease, immunology |
| Key Action | Audit any claims billing HCPCS S2107 or M0075 — Aetna explicitly lists both as non-covered for indications in this policy |
Aetna Adoptive Immunotherapy Coverage Criteria and Medical Necessity Requirements 2025
The central issue with CPB 0641 is this: the policy draws a hard line between diagnostic and procedural support codes on one side, and the core therapy codes on the other.
HCPCS S2107 covers adoptive immunotherapy — specifically the development of specific anti-tumor reactivity, including tumor-infiltrating lymphocyte therapy. HCPCS M0075 covers cellular therapy broadly. Aetna's coverage policy places both of these squarely in the "not covered" column for the indications listed in this bulletin.
The five CPT codes in this policy — 36511 (therapeutic apheresis for white blood cells), 86357 (natural killer cell total count), 88230 (tissue culture for non-neoplastic disorders, lymphocyte), 88237 (tissue culture for neoplastic disorders, bone marrow and blood cells), and 88239 (solid tumor tissue culture) — are grouped separately as "other CPT codes related to the CPB." That grouping matters for your billing team.
Aetna has not labeled those five CPT codes as non-covered outright. But they're tied to a policy where the primary therapy codes are denied. That means medical necessity documentation for any of these supporting codes needs to be airtight before you submit.
CPB 0641 does not specify prior authorization requirements in the available policy data. Check your Aetna provider agreement or contact Aetna provider services directly for PA guidance specific to your plan type.
The ICD-10 code universe attached to this policy is massive — 460 codes spanning infectious and parasitic diseases (A00.0 through B99.9), viral CNS infections, arthropod-borne fevers, herpesvirus conditions, and solid tumor diagnoses. That breadth tells you Aetna mapped this policy across a wide clinical population. It doesn't mean all those diagnoses unlock coverage. It means Aetna is tracking claims across all of them under this bulletin.
Aetna Adoptive Immunotherapy and Cellular Therapy Exclusions and Non-Covered Indications
This is where your reimbursement risk lives. Aetna's CPB 0641 explicitly marks two HCPCS codes as non-covered for the indications listed in this policy.
S2107 — adoptive immunotherapy including tumor-infiltrating lymphocyte development — is not covered. M0075 — cellular therapy — is not covered. These aren't gray-area exclusions. Aetna states this directly in the policy grouping labels.
That's a claim denial waiting to happen if your team is billing these codes without recognizing the coverage wall. The real issue here is that both codes carry high unit costs. A single denied claim for S2107 or M0075 can represent significant revenue exposure, especially in oncology practices running multiple cases.
Review your claim history for any previously submitted S2107 or M0075 claims against Aetna to assess exposure under this policy's non-covered designations.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Adoptive immunotherapy (anti-tumor reactivity, tumor-infiltrating lymphocytes) | Not Covered | HCPCS S2107 | Explicitly excluded for indications listed in CPB 0641 |
| Cellular therapy (general) | Not Covered | HCPCS M0075 | Explicitly excluded for indications listed in CPB 0641 |
| Therapeutic apheresis for white blood cells | Related — coverage status tied to indication | CPT 36511 | Grouped as "other CPT codes related to the CPB"; medical necessity documentation required |
| Natural killer cell total count | Related — coverage status tied to indication | CPT 86357 | Grouped as "other CPT codes related to the CPB" |
| Lymphocyte tissue culture (non-neoplastic) | Related — coverage status tied to indication | CPT 88230 | Grouped as "other CPT codes related to the CPB" |
| Tissue culture, bone marrow/blood cells (neoplastic) | Related — coverage status tied to indication | CPT 88237 | Grouped as "other CPT codes related to the CPB" |
| Solid tumor tissue culture | Related — coverage status tied to indication | CPT 88239 | Grouped as "other CPT codes related to the CPB" |
| Infectious and parasitic disease diagnoses (A00.0–B99.9) | Mapped to policy — not an automatic coverage trigger | ICD-10 range | 460 ICD-10 codes attached to policy scope; diagnosis alone doesn't establish coverage |
| Viral CNS infections (A80–A89) | Mapped to policy — not an automatic coverage trigger | ICD-10 range | See note above |
| Herpesvirus conditions (B10.x range) | Mapped to policy — not an automatic coverage trigger | ICD-10 range | See note above |
Aetna Adoptive Immunotherapy Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Review your claim history for any previously submitted S2107 or M0075 claims against Aetna. Assess your exposure under this policy's non-covered designations. Identify any paid claims and determine your risk if Aetna initiates a recoupment review. |
| 2 | Stop billing S2107 and M0075 for the indications covered in CPB 0641 without a documented coverage exception or appeals strategy in place. These codes are explicitly listed as not covered. Continuing to submit them without a plan creates clean-claim risk and wastes staff time on predictable denials. |
| 3 | Review your charge capture for CPT 36511, 86357, 88230, 88237, and 88239 before submitting any Aetna claims after October 2, 2025. These codes aren't marked non-covered, but they live inside a policy where the primary therapy codes are excluded. Your documentation needs to show why the supporting service is medically necessary independent of the non-covered therapy. |
| 4 | Check prior authorization requirements for each Aetna plan type you bill. CPB 0641 does not specify PA requirements in the available policy data. Contact Aetna provider services directly or consult your provider agreement for PA guidance specific to your plan type and market. |
| 5 | Map your ICD-10 coding against the 460 diagnosis codes attached to this policy. If you're billing for patients with diagnoses in the A00–B99 infectious disease range or the B10 herpesvirus range, Aetna is already flagging those claims for review under CPB 0641. Your documentation should clearly support medical necessity for any associated procedure code. |
| 6 | Talk to your compliance officer before submitting any off-label or investigational use claims tied to S2107 or M0075. If your practice is involved in clinical research or emerging cellular therapy protocols, the non-covered designation here has compliance implications beyond just denied claims. Get your legal counsel and compliance officer involved before the effective date creates a retroactive problem. |
| 7 | Set up a denial tracking workflow specifically for CPB 0641 claim denials. If you're seeing S2107 or M0075 denials increase after October 2, 2025, that's your signal to audit the full claim population and evaluate whether appeals are viable. If you pursue appeals for denied S2107 or M0075 claims, consult Aetna's provider manual for applicable appeals documentation requirements. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Adoptive Immunotherapy and Cellular Therapy Under CPB 0641
CPT Codes Related to CPB 0641
These codes are grouped as related to the policy. Coverage depends on the specific indication and supporting documentation.
| Code | Type | Description |
|---|---|---|
| 36511 | CPT | Therapeutic apheresis; for white blood cells |
| 86357 | CPT | Natural killer (NK) cells, total count |
| 88230 | CPT | Tissue culture for non-neoplastic disorders; lymphocyte |
| 88237 | CPT | Tissue culture for neoplastic disorders; bone marrow, blood cells |
| 88239 | CPT | Solid tumor (tissue culture) |
HCPCS Codes — Not Covered for Indications in CPB 0641
| Code | Type | Description | Status |
|---|---|---|---|
| S2107 | HCPCS | Adoptive immunotherapy i.e., development of specific anti-tumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) | Not covered for indications listed in CPB 0641 |
| M0075 | HCPCS | Cellular therapy | Not covered for indications listed in CPB 0641 |
Key ICD-10-CM Diagnosis Codes Mapped to CPB 0641
Aetna attached 460 ICD-10-CM codes to this policy. The table below covers the primary code ranges. This is not an exhaustive list — pull the full code set from the source policy at PayerPolicy before building your billing workflow.
| Code / Range | Description |
|---|---|
| A00.0–B99.9 | Certain infectious and parasitic diseases (full chapter range) |
| A08.0–A08.8 | Viral and other specified intestinal infections |
| A80–A89 | Viral and prion infections of the central nervous system |
| A90–A98 | Arthropod-borne viral fevers and viral hemorrhagic fevers |
| B0–B1 | Viral infections characterized by skin and mucous membrane lesions |
| B10.10–B10.19 | Other human herpesviruses (subgroup 1) |
| B10.20–B10.29 | Other human herpesviruses (subgroup 2) |
| B10.30–B10.39 | Other human herpesviruses (subgroup 3) |
| B10.40–B10.47 | Other human herpesviruses (subgroup 4) |
The ICD-10 range here spans infectious disease, viral CNS conditions, hemorrhagic fevers, and herpesvirus subtypes. If your patients carry diagnoses in these ranges and you're billing the related CPT codes, expect Aetna to review those claims under CPB 0641 billing guidelines.
Get the Full Picture for CPT 36511
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.